<DOC>
	<DOCNO>NCT02989194</DOCNO>
	<brief_summary>This Phase 2a randomize , double-blind , placebo-controlled study design ass safety tolerability VIS410 subject uncomplicated influenza .</brief_summary>
	<brief_title>Study VIS410 Subjects With Uncomplicated Influenza A</brief_title>
	<detailed_description>Subjects admit infusion unit drug administration observation follow infusion . The study design compare infusion single high low IV dose VIS410 placebo . Subjects follow 100 ( ±7 day ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Male female subject age ≥18 year ˂65 year Women fulfill one follow criterion : 1 . Postmenopausal ; either amenorrhea ≥12 month follicle stimulate hormone &gt; 40 mIU/mL document medical history 2 . Surgically sterile ; hysterectomy , bilateral oophorectomy , tubal ligation 3 . Women childbearing potential participate heterosexual sexual relation must willing use adequate contraception screen 60 day post infusion Nonvasectomized ( vasectomize less 6 month prior dose ) male subject female partner childbearing potential must use effective birth control method heterosexual intercourse , screen 60 day post infusion Test positive influenza A Rapid Antigen Test perform commercially available test adequate nasopharyngeal specimen accordance manufacturer 's instruction Presence least one respiratory symptom ( cough , sore throat , nasal symptom ) moderate severe intensity , presence least one constitutional symptom ( myalgia [ ache pain ] , headache , feverishness , fatigue ) moderate severe intensity Onset symptom ( time temperature first measure elevate [ temperature ≥100.4°F ≥38°C ] , OR time subject experience least one respiratory symptom least one constitutional symptom ) 72 hour start infusion Use NSAIDs antihistamine within 6 hour study drug dose exception use part pretreatment regimen History intolerance allergic response monoclonal antibody and/or pretreatment medication ( diphenhydramine , ibuprofen acetylsalicylic acid ) Subject weight le ( &lt; ) 45 kg Subjects clinical history would lead increase risk influenza complication include limited clinically significant cardiac disease , moderate severe asthma , moderate severe chronic obstructive pulmonary disease , metabolic syndrome include moderate severe diabetes active tuberculosis History chronic GI disease , include bleeding , ulceration , Irritable Bowel Syndrome , systemic mastocytosis chronic diarrhea Women pregnant , breastfeeding , consider become pregnant Patients hypoxemia require oxygen support Clinical evidence worsen chronic medical condition ( temporally associate onset symptom influenza ) , Investigator 's opinion , indicate find ( ) could represent complication influenza Presence immunocompromised status due chronic illness , previous organ transplant , use immunosuppressive medical therapy include systemic steroid Presence know Acquired Immune Deficiency Syndromedefining illness , chronic hepatitis B hepatitis C Receipt dose antiviral therapy , limited , rimantadine , amantadine , peramivir , zanamivir , laninamivir oseltamivir 7 day prior screen Enrollment investigational drug device study , disease vaccine study within 30 day prior Day 1 within 5 halflives investigational compound , whichever long Subjects unable take oral predose medication Known suspect alcohol drug abuse , , abuse level would compromise safety cooperation subject opinion Investigator Subjects chronic medication dose stable least 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>